Losartan and Levothyroxine Interaction: Safety, Timing, and What Your Doctor Monitors
Losartan (brand name Cozaar), an angiotensin II receptor blocker (ARB), is used to treat high blood pressure and to help protect the kidneys in certain patients with type 2 diabetes. Levothyroxine (brand names Synthroid, Levoxyl, Tirosint, and others) is a man-made version of thyroxine (T4) that replaces inadequate thyroid hormone in patients with hypothyroidism. Because losartan and levothyroxine work through different physiological pathways, they are often used concurrently in the same patient.
Losartan and levothyroxine have no recognized pharmacokinetic or pharmacodynamic drug-drug interaction. Losartan is metabolized hepatically, largely through CYP2C9, to its active metabolite; levothyroxine is not a CYP substrate and is not known to compete with losartan at any shared enzyme or transporter. The practical issue is not a drug interaction in the classic sense but an absorption-timing concern that applies to levothyroxine and almost any co-administered oral substance: levothyroxine absorption is dose-sensitive and is reduced by food, coffee, and many other oral medications and supplements taken at the same time, so it is generally dosed on an empty stomach, separated from other medications by an interval that manufacturer labeling and thyroid society guidance describe in the range of 30 to 60 minutes. This is a labeling and guideline-level recommendation for levothyroxine generally, not a losartan-specific warning.
What is established, what is plausible, and what is not settled
This combination sits at an unusual intersection: a well-described absorption principle for levothyroxine, and a much softer, population-level association between thyroid status and blood pressure. Those two things get conflated in casual discussion, so it is worth separating them explicitly.
Why these two drugs are often prescribed together
Hypothyroidism and hypertension are both common conditions, and it is unsurprising that many patients are managed for both simultaneously. Thyroid hormone deficiency is understood physiologically to increase peripheral vascular resistance, and correcting it can shift blood pressure control in a beneficial direction. Losartan is a standard first-line antihypertensive and is also used off the top of the ARB class when renal protection is a goal in patients with diabetic nephropathy. Patients on levothyroxine for Hashimoto thyroiditis, post-thyroidectomy, or post-radioactive iodine ablation frequently need an antihypertensive on a separate schedule, and losartan is a common choice for reasons unrelated to their thyroid status.
Where the interaction actually lives: absorption, not metabolism
Levothyroxine is absorbed mainly in the small intestine, and its oral bioavailability is meaningfully lower and more variable when it is taken with food, coffee, calcium, iron, or many other oral drugs. Manufacturer prescribing information for levothyroxine products instructs patients to take the drug as a single dose on an empty stomach, generally 30 to 60 minutes before food or other oral medications, because many drugs and foods affect its absorption. Losartan does not chelate thyroxine the way calcium carbonate or ferrous sulfate do, and it is not listed as a specific levothyroxine absorption interactant in FDA labeling or in major interaction databases such as those used by pharmacists (Lexicomp, Micromedex). The safest framing is: losartan is not a known levothyroxine absorption inhibitor, but taking any oral medication at the same moment as levothyroxine introduces an avoidable variable in gastric conditions and transit time, and consistent separation is the lower-risk habit regardless of what the second drug is.
Losartan itself is metabolized through CYP2C9 (with a minor CYP3A4 contribution) to its active carboxylic acid metabolite. This pathway is not shared with levothyroxine, which is cleared primarily through sequential deiodination in peripheral tissue rather than hepatic CYP metabolism. There is no established CYP or transporter-level conflict between the two drugs.
How to time the doses
The general, guideline-level approach for levothyroxine timing, which applies whether or not a patient also takes losartan, is:
- Take levothyroxine on a consistent schedule, on an empty stomach, with plain water.
- Wait at least 30 to 60 minutes before eating or taking other oral medications, including losartan.
- Keep calcium, iron, and antacid products separated from levothyroxine by a longer interval (commonly 4 hours), since these have a documented chelation effect that losartan does not share.
Some patients find a strict morning fasting window impractical. Bedtime dosing of levothyroxine, taken at least two to three hours after the last meal, is an alternative schedule that has been studied and is used in clinical practice; it allows losartan and other daytime medications to be taken without a morning conflict. A patient considering a schedule change should discuss it with their prescriber rather than switching unilaterally, since a TSH recheck is reasonable after any sustained change in dosing routine.
Liquid and softgel levothyroxine formulations are marketed as less sensitive to co-administered food and drugs than standard tablets, based on manufacturer and pharmacokinetic data; a patient with persistent TSH instability despite good timing adherence may be a candidate for a formulation change, decided with their prescriber rather than through self-substitution, since these products are not automatically interchangeable at the same dose.
The blood-pressure side of the relationship
Untreated or undertreated hypothyroidism is associated with increased peripheral vascular resistance and can make blood pressure harder to control. This relationship is described in the endocrine and cardiovascular literature at the level of physiological mechanism and observational association; it is not the same as a controlled trial showing that adding levothyroxine to a hypertensive, hypothyroid patient lowers blood pressure by a specific, reproducible amount. Clinically, it is plausible and commonly observed that a patient's antihypertensive requirement can change as thyroid status normalizes, which is why prescribers reassess blood pressure control and medication doses after a patient reaches a stable, euthyroid TSH rather than assuming the antihypertensive dose is fixed for life.
The reverse direction also matters. Over-replacement with levothyroxine (a suppressed TSH, sometimes below 0.1 mIU/L) can cause tachycardia, widened pulse pressure, and an increased risk of atrial fibrillation, particularly in older adults. In a patient also being treated for cardiovascular disease with losartan, iatrogenic thyrotoxicosis is an added cardiovascular stress that the ARB does not address. This is one of the practical reasons TSH monitoring is not optional once a patient is on levothyroxine, independent of what else they take.
Evidence-status assessment: losartan plus levothyroxine
| Claim | Status | Basis | What a clinician or pharmacist should verify |
|---|---|---|---|
| No shared CYP or transporter pathway between losartan and levothyroxine | Established | Losartan is a CYP2C9/3A4 substrate; levothyroxine clearance is via peripheral deiodination, not hepatic CYP metabolism. Consistent across FDA labeling and interaction databases. | Confirm current FDA label language has not changed at time of reader use. |
| Levothyroxine needs empty-stomach dosing separated from other oral drugs | Established (levothyroxine-general, not losartan-specific) | Manufacturer prescribing information and thyroid-society guidance for levothyroxine broadly. | Confirm the specific product's labeling (tablet vs. softgel vs. liquid) for its stated interval. |
| Losartan directly reduces levothyroxine absorption | Not established | No FDA labeling or major interaction database lists losartan as a levothyroxine absorption interactant, unlike calcium, iron, or PPIs. | If a patient's TSH rises after starting losartan, investigate adherence and timing before attributing it to the ARB itself. |
| Correcting hypothyroidism lowers blood pressure and may reduce losartan dose needs | Plausible, mechanism-supported, magnitude uncertain | Physiological and observational literature links hypothyroidism to increased vascular resistance; the size and consistency of blood pressure change after treatment varies across studies. | Do not down-titrate losartan based on this association alone; reassess with actual blood pressure readings after TSH stabilizes. |
| Losartan interacts meaningfully with potassium-sparing diuretics, NSAIDs, and lithium | Established (FDA labeling, class-level pharmacology) | These are labeled ARB-class interactions independent of thyroid status. | Screen for these specifically; they carry materially higher risk than the levothyroxine timing question. |
| A specific numeric TSH monitoring interval after adding losartan | Not established as losartan-specific | Standard levothyroxine monitoring intervals apply; no evidence that losartan changes them. | Follow the patient's existing thyroid monitoring plan; do not add extra labs solely because losartan was started. |
Monitoring: what actually needs to be tracked
No monitoring test is required specifically because a patient takes both drugs together. The two monitoring plans run in parallel:
Thyroid monitoring. TSH is generally checked roughly six to eight weeks after starting levothyroxine or changing its dose, and at longer intervals once stable. A meaningful, sustained change in dosing schedule (for example, switching from morning to bedtime dosing) is a reasonable trigger for a recheck, since absorption can shift.
Losartan monitoring. Serum creatinine and potassium are typically checked within the first few weeks of starting or increasing losartan and periodically afterward, per standard ARB-class monitoring practice, particularly in patients with diabetes or reduced kidney function. This monitoring is unaffected by whether the patient also takes levothyroxine.
Blood pressure targets. Guideline blood pressure targets for most adults with hypertension are generally below 130/80 mmHg, per current cardiology guidance current as of this writing; a prescriber may reconsider the losartan dose if blood pressure improves meaningfully after a patient's thyroid status stabilizes, but this is a case-by-case clinical judgment, not an automatic step.
Losartan interactions that carry more real-world risk than levothyroxine
Levothyroxine is a low-risk co-prescription for losartan. Other losartan interactions carry more clinical weight and deserve more attention from patients and pharmacists:
- Potassium-sparing diuretics (such as spironolactone or eplerenone). Combined use raises the risk of hyperkalemia, particularly with reduced kidney function.
- NSAIDs (ibuprofen, naproxen, and similar drugs). Regular NSAID use can blunt losartan's blood-pressure-lowering effect and, especially in combination with a diuretic, raises the risk of acute kidney injury.
- Lithium. ARBs including losartan can reduce lithium clearance and raise lithium levels toward a toxic range; this is a labeled warning and requires closer lithium level monitoring if the combination is used.
- Drugs that strongly affect CYP2C9 (certain enzyme inducers and inhibitors) can alter conversion of losartan to its active metabolite and may change its antihypertensive effect; a pharmacist review is reasonable when starting a new interacting drug.
By comparison, levothyroxine does not appear on FDA labeling or major pharmacist-facing interaction databases as a losartan interactant; it is generally classified, at most, as a "monitor spacing" situation rather than a true interaction.
Special situations
Older adults. Absorption of levothyroxine can be less predictable, and losartan clearance may be slower. Starting doses of both drugs are often lower in this population, with slower titration and closer monitoring, decided individually with a prescriber.
Pregnancy. Levothyroxine requirements typically increase in pregnancy, often early on. Losartan carries an FDA warning against use in pregnancy because of fetal risk, particularly in the second and third trimesters. Anyone who could become pregnant and is taking both drugs should have an explicit plan, made with their prescriber, for stopping losartan and switching to a pregnancy-appropriate antihypertensive before conception, not after a positive test.
Chronic kidney disease. Losartan is used specifically for renal protection in some patients with diabetic kidney disease, based on trial evidence for that population. Levothyroxine clearance and requirements can shift in advanced CKD, which is a reason for closer thyroid monitoring in that group, independent of losartan.
Patient counseling points
- Take levothyroxine at a consistent time, on an empty stomach, with plain water, and wait at least 30 to 60 minutes before eating, drinking coffee, or taking losartan or other medications.
- If bedtime dosing works better for your routine, ask your prescriber whether it is appropriate for you rather than switching on your own.
- Keep calcium, iron, and antacids separated from levothyroxine by a longer gap than other medications, since these have a stronger, documented absorption effect.
- Report symptoms that suggest undertreated hypothyroidism (fatigue, weight gain, cold intolerance, constipation) or symptoms suggesting losartan-related problems (lightheadedness, muscle weakness suggesting high potassium).
- Do not stop either medication without talking to your prescriber first.
- If your levothyroxine brand or formulation changes, ask about a follow-up TSH check.
The bottom line
Losartan and levothyroxine do not share a metabolic pathway, and neither drug's labeling lists the other as a direct interactant. The real-world issue is that levothyroxine absorption is sensitive to almost anything taken at the same time, so consistent, separated dosing protects thyroid control regardless of what antihypertensive a patient takes. Thyroid status and blood pressure are physiologically linked, and it is reasonable for a prescriber to reassess a patient's losartan dose once their thyroid levels are stable, but that reassessment should be based on measured blood pressure, not assumed automatically.
Frequently asked questions
Can I take losartan with levothyroxine?
What happens if I take losartan and levothyroxine at the same time?
Does losartan affect thyroid lab results?
Should I take levothyroxine in the morning or at bedtime if I also take losartan?
What are the most important losartan interactions to know about?
Could treating my hypothyroidism reduce how much losartan I need?
References and further reading
This article draws on FDA prescribing information for losartan and levothyroxine products, American Thyroid Association guidance on levothyroxine dosing and timing, and general cardiovascular and endocrine literature on the relationship between thyroid status and blood pressure. Specific numeric findings attributed to individual studies in earlier drafts of this article could not be verified against a checked primary source and have been removed or rephrased as general, mechanism-level statements pending editorial verification. Readers and reviewing clinicians should confirm any precise study statistic against the primary literature (for example, via PubMed) before it is restored to the page, and should check current FDA labeling directly for the most up-to-date prescribing information on both drugs.